#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis
- Authors:
- A Clamp, I Mcneish, R Lord, M Hall, S Essapen, A Cook, R Agarwal, A Walther, S Blagden, D O’Donnell, JD Brenton, S Sundar, C Sessa, A Cook, D Radice, F Schiavone, A Gentry-Maharaj, R Kaplan, MK Parmar, J Ledermann
- Journal:
- Late Breaking Abstracts
- Publication date:
- 1st Sep 2023
- Full text
- DOI